Skip to main navigation Skip to search Skip to main content

Erratum to The emergence of new psychoactive substance (NPS) benzodiazepines: a review (Drug Testing and Analysis, (2018), 10, 1, (37-53), 10.1002/dta.2211)

  • Kieran R. Manchester
  • , Emma C. Lomas
  • , Laura Waters
  • , Fiona C. Dempsey
  • , Peter D. Maskell

    Research output: Contribution to journalComment/debatepeer-review

    Abstract

    This article corrects: Manchester KR, Lomas EC, Waters L, Dempsey FC, Maskell PD. The emergence of new psychoactive substance (NPS) benzodiazepines: A review. Drug Test Anal. 2018;10:392–393. https://doi.org/10.1002/dta.2211 References appearing in Table of this article were omitted from the original. Benzodiazepine patent years and EMCDDA report years (Table presented.).

    Original languageEnglish
    Pages (from-to)392-393
    Number of pages2
    JournalDrug Testing and Analysis
    Volume10
    Issue number2
    DOIs
    Publication statusPublished - 1 Jan 2018

    UN SDGs

    This output contributes to the following UN Sustainable Development Goals (SDGs)

    1. SDG 3 - Good Health and Well-being
      SDG 3 Good Health and Well-being

    Fingerprint

    Dive into the research topics of 'Erratum to The emergence of new psychoactive substance (NPS) benzodiazepines: a review (Drug Testing and Analysis, (2018), 10, 1, (37-53), 10.1002/dta.2211)'. Together they form a unique fingerprint.

    Cite this